表紙:頭頸部扁平上皮癌(HNSCC)市場:1次調査(KOLの洞察) - 市場インテリジェンス - 疫学と2033年までの市場予測
市場調査レポート
商品コード
1307859

頭頸部扁平上皮癌(HNSCC)市場:1次調査(KOLの洞察) - 市場インテリジェンス - 疫学と2033年までの市場予測

Head and Neck Squamous Cell Carcinoma (HNSCC)| Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2033

出版日: | 発行: Mellalta Meets LLP | ページ情報: 英文 252 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.09円
頭頸部扁平上皮癌(HNSCC)市場:1次調査(KOLの洞察) - 市場インテリジェンス - 疫学と2033年までの市場予測
出版日: 2023年06月30日
発行: Mellalta Meets LLP
ページ情報: 英文 252 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

頭頸部扁平上皮癌(HNSCC)市場は、外科的切除、放射線療法、化学療法、セツキシマブ、免疫療法といった現在の標準治療が大きく貢献しています。2033年までには、新たな新規治療法の導入と発売により、市場は変化すると予想されます。HNSCCの治療環境では、現在のSoCは低下し、新規の新興治療薬が最も高い市場シェアを握ると思われます。主要7ヶ国(米国、フランス、ドイツ、イタリア、スペイン、英国、日本)におけるHNSCC治療のための新興治療薬の売上は、2019年~2033年の調査期間中に高成長を遂げ、2033年までに75億米ドルに達すると予測されています。

当レポートでは、世界の頭頸部扁平上皮癌(HNSCC)市場について調査し、市場の現状とともに、症例数の動向、患者動向、競合製品の市場における位置づけ、市場の機会などを提供しています。

目次

エグゼクティブサマリー

  • 主な調査結果

頭頸部扁平上皮癌(HNSCC)疾患の背景

  • 頭頸部扁平上皮癌(HNSCC)の定義
  • 頭頸部扁平上皮癌の生物学
  • 原因
  • 症状
  • 病因
  • HNSCCにおける分子変化
  • バイオマーカー
  • 診断

疫学と患者集団

頭頸部扁平上皮癌(HNSCC)の疫学とモデルパラメータの主な情報源

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

現在の治療法と医療行為

アンメットニーズ

新しい治療法

  • パイプラインの概要
  • 頭頸部扁平上皮癌(HNSCC)の治療開発パイプライン
    • 製品分析
      • ASP-1929(Rakuten Medical Inc.)
      • ゼビナパント(Merck)
      • アテゾリズマブ(Roche)
      • ブパルリシブ(Adlai Nortye)
      • レンバチニブ+ ペンブロリズマブ(Merck/Eisai)
      • NBTXR3(Nanobiotix)
      • Eftilagimod alpha(Immutep)
      • ペトセムタブ(Merus)
      • HB-200(Hookipa Pharma)
      • エヴォルパセプト(ALX Oncology)
      • ティピファルニブ(Kura Oncology)
      • フィクラツズマブ(Aveo Oncology)

治療研究

価格調査

将来の治療パラダイム

現在の治療法と新しい治療法の年間コスト

市場の見通し

  • 主な調査結果
  • 2033年までの国別市場予測

国別市場予測

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

市場促進要因と抑制要因

目次
Product Code: MM20230021

The Head and neck squamous cell carcinoma (HNSCC) market is hugely contributed by current standard of care which are Surgical resection, radiotherapy, Chemotherapy, Cetuximab, Immunotherapy. By 2033, the market is expected to change due to the uptake and launch of new novel therapies. In a HNSCC treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of HNSCC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2019-2033 study period, adding a value estimated at a total market of $ 7.5 billion by 2033.

"Initial therapy may include combinations of surgery, radiation, and platinum-based chemotherapy but the recurrence after platinum based chemotherapy is associated with a particularly dismal prognosis. Average survival for these patients is less than 6 months. I have been treating patients for 20 years, the disease is devastating, with patients having significant issues with speech, swallowing, and breathing."

Head and Neck (H&N) Cancer's address tumors originating from the oral cavity (including the mucosal lip), pharynx, larynx, and paranasal sinuses. Squamous cell carcinomas account for more than 95% of these tumors. Tobacco and alcohol use disorders are the most common etiologies for oral cavity, hypopharynx, larynx, and Human Papillomavirus (HPV)-unrelated oropharynx cancers. Patients with H&N cancers due to tobacco and alcohol are at risk for harboring synchronous primary tumors and developing second primary neoplasms in the H&N, lung, esophagus, bladder, and other potential sites exposed to these carcinogens.

Surgical resection of the primary tumor and draining lymph nodes followed by risk-adapted adjuvant radiation, with or without platinum-based chemotherapy, or primary definitive concurrent chemoradiation, remain the principal treatments employed for locally advanced HNSCC. It is important to note that multimodality treatment often drastically impacts patient quality of life (QOL). Treatment planning should aim for the most highly curative approach, while optimizing preservation of function.

Recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC) is a challenging disease with limited treatment options. It is often diagnosed when the cancer has spread to other parts of the body or has returned after treatment. The prognosis for RM HNSCC is poor, with a median overall survival of just a few months. However, recent advances in immunotherapy and targeted therapy have shown promise in improving outcomes for some patients with RM HNSCC. Clinical trials are ongoing to determine the most effective treatment strategies for this aggressive form of cancer. Early diagnosis and aggressive treatment are critical to improving survival outcomes for patients with RM HNSCC.

Head and neck squamous cell carcinoma (HNSCC) - Epidemiology

The total HNSCC incident cases in the G7 countries are anticipated to increase to 150,447 cases by 2033 for the study period (2019- 2033). As per estimates, the EU5 accounted for the highest incidence of Head and neck squamous cell carcinoma (HNSCC) cases in 2023 which was 63,239 cases and is expected to increase by 2033 for the study period followed by the United States and Japan. Among the EU5, France had the highest AML cases, followed by Germany, the United Kingdom, Spain, and Italy.

Head and neck squamous cell carcinoma (HNSCC) - Current Market Size & Forecast Trends

The Head and neck squamous cell carcinoma (HNSCC) therapeutics market is expected to experience high growth throughout the study period (i.e., 2019 to 2033) and reach USD 7.5 billion, representing a compound annual growth rate (CAGR) of 13.9%.

The United States captured the highest market share in 2023 compared to the European 5 countries and Japan. The significant growth in the market can be attributed to the strategic adoption strategies implemented by key market players. By 2033, the market share of the United States is projected to increase to USD 4.5 billion, while the European 5 countries and Japan are expected to have substantial market sizes.

During the forecast period (2019-2033), the market growth is expected to grow which is attributed to the several therapies which are currently launched specially in the R/M segments of the HNSCC market. We are expecting the drug utilization of the therapies will further increase including Anti-PD-1, EGFR inhibitors. These established therapies play a pivotal role in addressing Head and neck squamous cell carcinoma, improving patients' quality of life. Secondly, the introduction of innovative drugs such as ASP-1929 (Rakuten Medical Inc.), Xevinapant (Merck), Atezolizumab (Roche), Buparlisib (Adlai Nortye), Lenvatinib + Pembrolizumab (Merck/Eisai), NBTXR3 (Nanobiotix), Petosemtamab (Merus) adds further momentum to the market expansion, ensuring a comprehensive range of treatment options for patients.

Report Highlights:

  • Head and neck squamous cell carcinoma (HNSCC) - Current Market Trends
  • Head and neck squamous cell carcinoma (HNSCC) - Current & Forecasted Cases across the G7 Countries
  • Head and neck squamous cell carcinoma (HNSCC) - Market Opportunities and Sales Potential for Agents
  • Head and neck squamous cell carcinoma (HNSCC) - Patient-based Market Forecast to 2033
  • Head and neck squamous cell carcinoma (HNSCC) - Untapped Business Opportunities
  • Head and neck squamous cell carcinoma (HNSCC) - Product Positioning Vis-a-vis Competitors' Products
  • Head and neck squamous cell carcinoma (HNSCC) - KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Head and neck squamous cell carcinoma (HNSCC) Disease Background

  • Head and neck squamous cell carcinoma (HNSCC) Definition
  • Biology of Head and Neck Squamous Cell Carcinoma
  • Causes
  • Symptoms
  • Pathogenesis
  • Molecular Alterations in HNSCC
  • Biomarkers
  • Diagnosis

Epidemiology and Patient Populations

  • Key Findings
  • Methods and Data Sources
    • Country Specific Incident Cases of Head and neck squamous cell carcinoma (US, Germany, France, Italy, Spain, UK, and Japan)
    • Country Specific Stage Specific Cases of Head and neck squamous cell carcinoma (HNSCC)

Key Sources for Head and neck squamous cell carcinoma (HNSCC) Epidemiology and Model Parameters

  • United States
    • United States incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • United States stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • Germany
    • Germany incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • Germany stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • France
    • France incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • France stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • Italy
    • Italy incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • Italy stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • Spain
    • Spain incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • Spain stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • United Kingdom
    • United Kingdom incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • United Kingdom stage specific cases of Head and neck squamous cell carcinoma (HNSCC)
  • Japan
    • Japan incident cases of Head and neck squamous cell carcinoma (HNSCC)
    • Japan stage specific cases of Head and neck squamous cell carcinoma (HNSCC)

Current Therapies and Medical Practice

  • Drugs Approved in G7 countries
  • Treatment Algorithm & Future Product Positioning for Head & Neck Squamous Cell Carcinoma
  • Treatment of Practices in Head & Neck Squamous Cell Carcinoma (HNSCC)
  • Treatment Guidelines (2023 NCCN Guidelines, 2020 ESMO Guidelines)
  • SOC Data
  • Marketed Therapies

Unmet Needs

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Head and neck squamous cell carcinoma (HNSCC)
    • Product Analysis
      • ASP-1929 (Rakuten Medical Inc.)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • Xevinapant (Merck)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • Atezolizumab (Roche)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • Buparlisib (Adlai Nortye)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • Lenvatinib + Pembrolizumab (Merck/Eisai)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • NBTXR3 (Nanobiotix)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • Eftilagimod alpha (Immutep)
        • Product Profile
        • Clinical Development
      • Petosemtamab (Merus)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2033
      • HB-200 (Hookipa Pharma)
        • Product Profile
        • Clinical Development
      • Evorpacept (ALX Oncology)
        • Product Profile
        • Clinical Development
      • Tipifarnib (Kura Oncology)
        • Product Profile
        • Clinical Development
      • Ficlatuzumab (Aveo Oncology)
        • Product Profile
        • Clinical Development

Treatment Studies

  • Real-world Treatment Pattern as 2L R/M HNSCC: IO Monotherapy is being prescribed to 67% patients progressed on Platinum-based Chemotherapy
  • Treatment Patterns in Recurrent or Metastatic Head and Neck Cancer (R/M HNC) Patients in Japan

Pricing Studies

  • Total cost of care for patients with Advanced HNSCC
  • Clinical and economic burden of head and neck cancer: A nationwide retrospective cohort study from France

Future Treatment Paradigm

  • Head and neck squamous cell carcinoma (HNSCC) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings
  • Country Specific Market Forecast to 2033
    • Sales of Drugs to Treat Head and neck squamous cell carcinoma (HNSCC) in the Major Pharmaceutical Markets, 2019-2033
    • Patient Share of Head and neck squamous cell carcinoma (HNSCC) Therapies 2019-2033 (USD Million)

Market Forecast by Country

  • United States
    • United States Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • United States Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • Germany
    • Germany Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • Germany Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • France
    • France Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • France Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • Italy
    • Italy Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • Italy Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • Spain
    • Spain Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • Spain Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • United Kingdom
    • United Kingdom Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • United Kingdom Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)
  • Japan
    • Japan Market for Head and neck squamous cell carcinoma (HNSCC) 2019-2033 (USD Million)
    • Japan Market for Head and neck squamous cell carcinoma (HNSCC) by Therapies 2019-2033 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Head and neck squamous cell carcinoma (HNSCC)?
  • What Factors Are Constraining the Market for Head and neck squamous cell carcinoma (HNSCC)?